 LES HEALTH CARE SECTOR & LESI LIFE SCIENCES COMMITTEE
8:15 a.m. - 12:00 p.m.
How can licensing professionals improve performance, as the economic importance of licensing and technology deals continues to grow in the Healthcare Sector? Two panels of experts offer critical insights that will help you create strategic advantages and benchmark your performance against others in the healthcare industry. Join us as we explore innovative approaches to the use of IP in dealmaking and the remarkable results of the 2007 BioPharmaceutical Royalty Rate & Deals Terms Survey.
Prospecting for Deals: Intellectual Property Strategies that Drive Improvement in Licensing and Business Development Performance
Sourcing new products and technologies in life sciences has driven substantial growth and increased visibility for licensing and business development (L&BD) professionals. Big Pharma wants to be seen as a great partner for biotech companies, speed to complete transactions has become increasingly critical in the face of competitive bidding among Big Pharma companies for access to biotech opportunities, and deals have moved farther back in the R&D pipeline. Expanding the kinds of IP considerations used in the licensing and business development process can create new opportunities and strategic advantages. The first panel will focus on the overlap of licensing tactics and intellectual property strategies to increase value.
Experts in both L&BD and IP will discuss strategies for prospecting, target identification, opportunity assessment, and evaluation. Hear about innovative approaches to development of an IP strategy, beyond mere concern for freedom to operate. Learn how to incorporate IP strategy into deal making to increase the ROI on the growing investment of resources in the licensing and business development process. The value associated with the use of innovative IP strategies in L&BD will be highlighted by case histories of successful examples.
Gregory Bell, Executive Vice President, CRA International (USA)
Iain M. Cockburn, Professor, Boston University School of Management (USA)
Peter B. Corr, Pfizer (USA)
Mervyn J. Turner, PhD, Senior Vice President, Worldwide Licensing & External Research, Merck & Co., Inc. (USA)
Hidden Treasure: Recent Royalty Rates and Deal Terms from the LES 2007 Survey
This just in! The LES 2007 BioPharmaceutical Royalty Rate & Deals Terms Survey has yielded a gold mine of timely information, unavailable through any other source, with landmark data from over 250 submitted deals from the past three years, across multiple therapeutic areas and development stages, including contribution of hard-to-obtain data for a high number of preclinical deals. A panel of experts who have been mining the data will preview the results, reporting their first insights and key metrics resulting from the groundbreaking study. Included will be an overview of findings, specific highlights of the survey, a preview of data, and discussion of deal-making implications.
Launched at the LES meeting in Vancouver, the survey has produced revealing and contemporary results. The survey provides remarkable data that will allow LES members to benchmark themselves against other companies and industry standards. The LES Trustees commissioned Veris Consulting, a leading survey organization for professional associations, to provide current and meaningful data that supports the core business activity of LES members. A Survey Report will be published in the summer of 2008 exclusively to current LES members. Don't miss this advance preview, and the insights and analysis presented by industry experts familiar with the findings.
James A. McCarthy, Sr. Vice-President, Corporate Development, Expression Genetics, Inc. ,
Committee Chair, "2007 BioPharmaceutical Royalty Rate and Deal Terms Survey"
Steven Renwick, Ph.D., Manager, Strategic Intelligence, PharmaVentures
Ben Bonifant, Vice President, Business Development Practice, Campbell Alliance
Daniel M. McGavock, Vice President and IP Practice Leader, CRA International
 LES HIGH TECH SECTOR & LESI IT &
E-COMMERCE
8:15 a.m. - 12:00 p.m.
Patent Valuation - Is There One or Many?
As difficult as determining the technical merit of a patent may be, setting the financial value of patents and patent portfolios is a dark art. Is it possible there is no single correct value?
Consider present day litigation valuation techniques such as those derived from Georgia Pacific. Or, the value determined in fast rising patent auctions - with and without extensive engineering evaluation. Technology licensing often includes patent licenses, but at what value? What about patent license negotiations initiated to forestall the need for litigation? Is the valuation of a portfolio of patents the summation of the worth of the individual patents within? Do - or should - patent brokers arrive at yet another value? Based on evaluation, are essential patents more valuable than non-essential patents? Does the value of a patent change with stage? Finally, in a bankruptcy fire sale, what is fair?
A panel discussion directed at sharing thoughts on these questions will attempt to illuminate this matter. The audience will have ample opportunity to question what they hear or don't hear.
Brett Govett, Partner, Fulbright & Jaworski LLP (USA)
James E. Malackowski, President & Chief Executive Officer, Ocean Tomo (USA)
Donald W. Merino, General Manager Acquisitions, Intellectual Ventures (USA)
Tanya Moore, Director IP Licensing, Microsoft Corporation (USA)
Charles Neuenschwander, President, International Patent Licensing Company (USA)
Dwight C. Olson, Senior Advisor, CONSOR (USA)
Shirley Webster, Vice President, CRA International (USA)
 LEGAL
8:15 a.m. - 12:00 p.m.
Licensing Essential Patents and the Interplay with the Standards Development Organizations
The panelists for this session have various experiences in standards development, government review of the standards IP rules and licensing policies, as well as essential patent licensing experience. They will present their perspectives on the legal framework and business issues in working with standards development organizations and the issues surrounding essential IP to a standard. Among the topics to be discussed are the obligations contributors have to the standards development organization to disclose IP essential to a contribution and what it means to license essential patents on fair, reasonable and non-discriminatory terms.
Moderator:
Michael Stolarski, Partner, Howrey LLP (USA)
Michael Cowie, Partner, Howrey LLP (USA)
Kirk Dailey, Vice President, Intellectual Property, Motorola Inc. (USA)
Roberto Dini, CEO, Metroconsult (Italy)
Carter Eltzroth, Legal Director, DVB Project, European Broadcasting Union (Switzerland)
Larry Goldstein, Vice President- Intellectual Property, Patent Tools, and Licensing, Sedna Services (USA)
 LES CHEMICALS, ENERGY AND MATERIALS AND LESI CHEMICALS, ENERGY AND THE ENVIRONMENT
8:15 a.m. - 12:00 p.m.
Choices, Choices and More Choices for Fuels of the Future
While it is expected that fossil fuels will continue to play a significant role in energy sourcing, this mini-plenary session will examine some of the challenges and tensions in developing commercialization and widespread adoption of biofuels and fuel cells - and the licensing marketplace that is beginning to emerge. Speakers from different geographic regions of the world and different organizations - start-ups, government, universities and energy companies- will provide attendees a head start in unraveling the choices.
This mini-plenary will focus first on various new technologies being developed including an important initiative by DOE, the licensing models being used by leading non-profits, and financing perspectives; the second portion will focus on hydrogen and fuel cells.
Attendees will also be able to learn about the progress of FutureGen.
"FutureGen is an initiative to build the world's first integrated sequestration and hydrogen production research power plant. The $1.5 billion* project is intended to create the world's first zero-emissions fossil fuel plant. When operational, the prototype will be the cleanest fossil fuel fired power plant in the world. "
Moderator:
Ada C. Nielsen, Manager, Commercial Development, BP America, Inc. (USA)
Speakers:
Stephen Ban, Director, Office of Technology Transfer, Argonne National Laboratory(USA)
Walter G. Copan, Executive Vice President and Chief Technology Officer, Clean Diesel Technologies (USA)
James J. Greenberger, Partner, Reed Smith LLP (USA)
Lesley Millar, Director of the Office of Technology Management, University of Illinois at Urbana-Champaign (USA)
John Regan, Senior Director, IllinoisVENTURES and Partner, Illinois Emerging Technologies Fund
William W. Shilts, Chief, Illinois Geological Survey (USA)
Simran Trana, Director, Purdue Research Foundation (USA)
Sergio C. Trindade, SE2T International, Ltd (USA)
BIOMEDICAL DEVICES
8:15 a.m. - 12:00 p.m.
Global Medical Device Collaborations and Licensing: A Comparative View from Canada, Europe and the USA
This session will address issues arising in today's global collaborative environment. This workshop will discuss patent strategies to protect collaborations. A comparison of patent laws will address novelty/obviousness (Post-Teleflex); protecting therapies/device usage; and understanding patent opposition practice. Enforcement issues relating to medical devices, including comparative reviews of doctrine of equivalents, contributory infringement, and remedies (e.g.,EBAY injunctions) will be considered. Multi-national litigation concerns will also be addressed. Finally, defining expectations and responsibilities of collaborators and critical hurdles toward commercialization including regulatory differences across jurisdictions will be considered.
Moderator/Speakers:
Eric M. Dobrusin, Shareholder, Dobrusin & Thennisch PC (USA)
Martin Fäehndrich, Partner, Lovells LLP (Germany)
Anita Nador, Partner, McCarthy Tétrault (Canada)
Jacqueline Csonka-Peeren, Early Stage Technology Commercialization, BioAlliance Consulting Inc. (Canada)
|
